Currently, the biomarkers that are widely recognized by the medical community as being able to predict the prognosis of immunotherapy are PD-L1 CPS, microsatellite instability-high (MSI-H) and tumor mutation burden (TMB). The gene discussed is CD274; the disease is neoplasm.